Summary
Cencora, Inc. (COR) has filed a Form 8-K detailing an amendment to its securitization facility. Effective June 30, 2025, the company, through its subsidiaries, entered into a Twenty-Second Amendment to its Amended and Restated Receivables Purchase Agreement. This amendment is significant as it increases the overall capacity of the receivables securitization facility and enhances its flexibility, providing Cencora with greater access to liquidity for its ongoing business operations. Key changes include an increase in the facility size to $1.5 billion from $1.45 billion, and importantly, an expansion of the "Accordion Feature." This feature now allows Cencora to potentially increase commitments by an additional $500 million (up from $250 million) and makes this option available on a quarterly basis, subject to bank approval. The facility is crucial for funding operations by leveraging accounts receivables from pharmaceutical sales, with Cencora acting as a performance guarantor for its subsidiaries involved in the securitization process.
Key Highlights
- 1Cencora, Inc. amended its receivables securitization facility on June 30, 2025.
- 2The total size of the facility was increased to $1.5 billion, up from $1.45 billion.
- 3The "Accordion Feature" was enhanced, allowing for a potential increase of up to $500 million in commitments, a doubling from the previous $250 million.
- 4The Accordion Feature is now available to Cencora on a quarterly basis, providing more operational flexibility.
- 5The facility is designed to provide additional liquidity for the company's ongoing business needs.
- 6Funding is based on accounts receivables generated from the sale of pharmaceuticals and related products.
- 7Cencora serves as a performance guarantor for its subsidiaries' obligations under the facility.